Patent search ap:("AbbVie Inc.") AND inv:"Jeffrey W. Voss" Page 1

1.

发明授权
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms therof 有权

公开(公告)号：US11976077B2

公开(公告)日：2024-05-07

申请号：US18176651

申请日：2023-03-01

Applicant: AbbVie Inc.

Inventor： Aileen L. Pangan , Henrique D. Teixeira , Mohamed-Eslam F. Mohamed , Ahmed A. Othman , Ben Klünder , Jeffrey W. Voss , Robert J. Padley , Heidi S. Camp

IPC: C07D487/14 , A61K9/00 , A61K9/20 , A61K31/4985 , A61K47/12 , A61K47/38

CPC classification number: C07D487/14 , A61K9/0053 , A61K9/2013 , A61K9/2027 , A61K9/2054 , A61K31/4985 , A61K47/12 , A61K47/38 , C07B2200/13

Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.

2.

发明授权
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 有权

公开(公告)号：US11795175B2

公开(公告)日：2023-10-24

申请号：US18176647

申请日：2023-03-01

Applicant: AbbVie Inc.

Inventor： Mohamed-Eslam F. Mohamed , Ahmed A. Othman , Ben Klünder , Aileen L. Pangan , Jeffrey W. Voss , Robert J. Padley , Heidi S. Camp

IPC: A61K31/4985 , A61K47/12 , A61K47/38 , C07D487/14 , A61K9/00 , A61K47/02

CPC classification number: C07D487/14 , A61K9/0053 , A61K31/4985 , A61K47/02 , A61K47/38 , C07B2200/13

Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

3.

发明授权
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 有权

公开(公告)号：US11767326B2

公开(公告)日：2023-09-26

申请号：US18176653

申请日：2023-03-01

Applicant: AbbVie Inc.

Inventor： Aileen L. Pangan , Henrique D. Teixeira , Mohamed-Eslam F. Mohamed , Ahmed A. Othman , Ben Klünder , Jeffrey W. Voss , Robert J. Padley , Heidi S. Camp

IPC: A61K31/4985 , A61K47/12 , A61K47/38 , C07D487/14 , A61K9/00 , A61K9/20

CPC classification number: C07D487/14 , A61K9/0053 , A61K9/2013 , A61K9/2027 , A61K9/2054 , A61K31/4985 , A61K47/12 , A61K47/38 , C07B2200/13

Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.

4.

发明申请
NOVEL TRICYCLIC COMPOUNDS 审中-公开

公开(公告)号：US20180291029A1

公开(公告)日：2018-10-11

申请号：US15806104

申请日：2017-11-07

Applicant: AbbVie Inc.

Inventor： Neil WISHART , Maria A. Argiriadi , David J. Calderwood , Anna M. Ericsson , Bryan R. Fiamengo , Kristine E. Frank , Michael M. Friedman , Dawn M. George , Eric R. Goedken , Nathan S. Josephsohn , Biqin C. Li , Michael J. Morytko , Kent D. Stewart , Jeffrey W. Voss , Grier A. Wallace , Lu Wang , Kevin R. Woller

IPC: C07D487/14 , C07D513/14 , C07D498/14

Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

5.

发明授权
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 有权

公开(公告)号：US11993605B2

公开(公告)日：2024-05-28

申请号：US18176664

申请日：2023-03-01

Applicant: AbbVie Inc.

Inventor： Mohamed-Eslam F. Mohamed , Ahmed A. Othman , Ben Klünder , Aileen L. Pangan , Jaclyn Kay Anderson , Jeffrey W. Voss , Robert J. Padley , Heidi S. Camp

IPC: A61K31/4985 , A61K9/00 , A61K47/12 , A61K47/38 , C07D487/14

CPC classification number: C07D487/14 , A61K9/0053 , A61K31/4985 , A61K47/12 , A61K47/38 , C07B2200/13

Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis), kits, methods of synthesis, and products-by-process.

6.

发明授权
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof 有权

公开(公告)号：US11780848B2

公开(公告)日：2023-10-10

申请号：US18176848

申请日：2023-03-01

Applicant: AbbVie Inc.

Inventor： Mohamed-Eslam F. Mohamed , Ahmed A. Othman , Aileen L. Pangan , In-Ho Song , Ben Klünder , Jeffrey W. Voss , Robert J. Padley , Heidi S. Camp

IPC: A61K31/4985 , C07D487/14 , A61K9/00 , A61K47/12 , A61K47/38

CPC classification number: C07D487/14 , A61K9/0053 , A61K31/4985 , A61K47/12 , A61K47/38 , C07B2200/13

Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA) and methods for treating active ankylosing spondylitis (AS).

7.

发明申请
NOVEL TRICYCLIC COMPOUNDS 审中-公开

公开(公告)号：US20160222020A1

公开(公告)日：2016-08-04

申请号：US15017802

申请日：2016-02-08

Applicant: AbbVie Inc.

Inventor： Neil Wishart , Maria A. Argiriadi , David J. Calderwood , Anna M. Ericsson , Bryan A. Fiamengo , Kristine E. Frank , Michael M. Friedman , Dawn M. George , Eric R. Goedken , Nathan S. Josephsohn , Biqin C. Li , Michael J. Morytko , Kent D. Stewart , Jeffrey W. Voss , Grier A. Wallace , Lu Wang , Kevin R. Woller

IPC: C07D487/14 , A61K31/437 , C07D471/14 , A61K31/4985 , A61K45/06

CPC classification number: C07D487/14 , A61K31/437 , A61K31/4985 , A61K45/06 , C07D471/14 , C07D498/14 , C07D513/14

Abstract: The invention provides compounds of Formula (I) and Formula (II) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

8.

发明申请
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF 有权

公开(公告)号：US20250034157A1

公开(公告)日：2025-01-30

申请号：US18913645

申请日：2024-10-11

Applicant: AbbVie Inc.

Inventor： Ayman Allian , Jayanthy Jayanth , Mohamed-Eslam F. Mohamed , Mathew M. Mulhern , Fredrik Lars Nordstrom , Ahmed A. Othman , Michael J. Rozema , Lakshmi Bhagavatula , Patrick J. Marroum , Peter T. Mayer , Ahmad Y. Sheikh , Thomas B. Borchardt , Ben Klünder , Heidi S. Camp , Robert J. Padley , Jeffrey W. Voss

IPC: C07D487/14 , A61K9/00 , A61K31/4985 , A61K47/02 , A61K47/12 , A61K47/38 , C07D487/04

Abstract: The present disclosure relates to solid-state forms and corresponding pharmaceutical compositions of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, and methods of treatment, including treatment of rheumatoid arthritis and juvenile idiopathic arthritis using the same. The treatment methods generally comprise administering to a patient (e.g., a pediatric patient) a therapeutically effective amount of upadacitinib as a stable liquid pharmaceutical composition or a solid dosage form, at a dose based on patient body weight.